Navigation Links
Two Studies Test Impact of Drugs to Slow Progression of Type 1 Diabetes
Date:6/27/2011

5 people, ages 3 to 45, with newly diagnosed type 1 diabetes. Participants were randomized into three groups to receive two or three doses of GAD-alum or alum alone over 4 to 12 weeks. During one year of treatment, the vaccine showed no evidence of preserving insulin secretion.

Adverse effects were minimal for both drugs, especially among children, who account for the majority of people with type 1 diabetes.  

"We learn something important from every study, and we build on everything we learn.  Both positive and negative studies help us develop more effective strategies to prevent and treat type 1 diabetes," said TrialNet Study Group Chair Jay Skyler, M.D. "We will continue to follow people in both studies.  It is still early, but there is good reason to believe that some of the drugs being developed to alter immune responses, either alone or in combination with other therapies, will lead to treatments that prevent, postpone, or stop progression of type 1 diabetes."

Type 1 diabetes is an autoimmune disease that accounts for 5 to 10 percent of diagnosed cases of diabetes in the United States—up to 2.5 million people. It develops when a person's own immune system destroys beta cells in the pancreas. Beta cells sense blood glucose and produce the hormone insulin, which regulates glucose levels and converts it to energy. Formerly called juvenile onset diabetes, type 1 diabetes usually develops in children and young adults. To maintain good control of their blood glucose levels, people with this form of diabetes typically need three or more insulin injections a day or treatment with an insulin pump, as well as careful monitoring of blood glucose and attention to diet and exercise.  Well controlled glucose is critical to preventing or delaying serious damage to the eyes, nerves, kidneys, heart, and blood vessels.

The destruction of insulin producing cells by the immune system begins well before the symptoms of diabet
'/>"/>

SOURCE TrialNet
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Studies Show Effect of BYDUREON™ on A1C and Weight for Up to Three Years
2. Pearl Therapeutics Advances Its Long-Acting Bronchodilator Combination Product Candidate into Four Additional Phase 2 Studies
3. Best of ASCO Features Two Studies Led by US Oncology Research Affiliated Physicians
4. Data from Clinical Studies of bioTheranostics CancerTYPE ID® and Breast Cancer Index(SM) Molecular Diagnostic Tests Presented at ASCO 2011 Annual Meeting
5. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
6. Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
7. Additional Data From Multiple Phase 1 and 2 Studies of S*BIOs Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
8. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
9. Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
10. Lilly Oncology to Unveil Data From More Than 30 Studies at ASCO
11. New Studies Support CardioFocus HeartLight™ Endoscopic Ablation Systems Notable Treatment Results for Paroxysmal Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 20, 2014  The acceptance of two abstracts ... Global Congress demonstrates continued interest in the Eclipse ... bowel control. One of the abstracts, presented by ... Chief of Urogynecology and Reconstructive Pelvic Surgery at ... for Best Written Abstract on Urogynecology/Pelvic Floor Disorders/Vaginal ...
(Date:11/21/2014)... Nov. 20, 2014 Oxis International, Inc. (OXIS) (OXI.PA) ... election of Anthony J. Cataldo as Chief Executive ... Effective November 19, 2014, Ken Eaton resigned his ... of Directors of Oxis International, Inc. to pursue new opportunities. ... named Chief Executive Officer of Oxis International, Inc. Mr. Cataldo ...
(Date:11/18/2014)... , Nov. 18, 2014  NxStage ® ... a leading manufacturer of innovative dialysis products ... Streamline® Express dialyzer for the in-center, hemodialysis ... set, which is designed to reduce the amount ... reduce the number of touch point contamination sites.  ...
Breaking Medicine Technology:LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 2LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 3OXIS International, Inc. announces Changes in Management Team 2OXIS International, Inc. announces Changes in Management Team 3NxStage Launches New Streamline Express Dialyzer With Pre-attached Blood Tubing Set 2
(Date:11/21/2014)... -- Seeking to make it tougher for people to ... on Thursday approved a new hydrocodone tablet that,s designed ... by the brand name Vicodin -- is a powerful ... in dangerous addictions across the United States. The ... is an extended-release tablet to treat pain severe enough ...
(Date:11/21/2014)... they,ve mapped the genome -- the genetic "blueprint" -- of ... it might help others with this very rare infection. ... , the tapeworm was removed from the brain of a ... so rare worldwide and completely unexpected in this country that ... pulled out from the brain," study lead author Hayley Bennett, ...
(Date:11/21/2014)... November 21, 2014 Center for Autism ... titled “Massachusetts Insurance Funding for Autism Workshops” to help ... their way through the insurance coverage process. Parents ... law and the most effective ways to access coverage. ... 4 from 6-8:00 p.m. at 331 Montvale Ave., 5th ...
(Date:11/21/2014)... 21, 2014 Big Bud Farms announced ... episode of Innovations with Ed Begley Jr., airing via ... TBA. , Big Bud Farms, growers of legal medical ... and utilization of medical marijuana. , This segment of ... wide variety of products for medicating. Viewers will learn ...
(Date:11/21/2014)... 2014 Launched today on the iTunes ... all-in-one senior care coordination tool designed to make tracking ... and intuitive for family members and caregivers (e.g. physicians ... the family caregiver or home health aide providing care ... data, medical records, goals, schedules, and even final plans ...
Breaking Medicine News(10 mins):Health News:FDA Approves 'Abuse-Resistant' Narcotic Painkiller 2Health News:FDA Approves 'Abuse-Resistant' Narcotic Painkiller 3Health News:Ick! Tapeworm Infecting Man's Brain Yields Genetic Secrets 2Health News:Center for Autism and Related Disorders to Host Massachusetts Autism Insurance Workshops for Parents 2Health News:Big Bud Farms to be Featured in Upcoming Episode of Innovations with Ed Begley Jr. 2Health News:Comprehensive Senior Care Application Launched on Apple App Store 2
... LOS ANGELES, Nov. 8 Response Genetics, Inc.,(Nasdaq: ... development of molecular,diagnostic tests for cancer, today announced ... financial results in a press release on,Wednesday, November ... Response Genetics, Inc. ("RGI") is engaged in the ...
... EMPLOYERS(R) (NYSE: EIG ),a leading ... a,new partnership with the California Restaurant Association ... compensation insurance with a,special CRA membership discount. ... http://www.newscom.com/cgi-bin/prnh/20061030/LAM128LOGO ) "We are enthusiastic ...
... 8 DATATRAK International,Inc. (Nasdaq: DATA ), a ... the clinical trials industry, today reported its,operating results for ... For the three months ended September 30, 2007, ... net loss of $(3,506,000), or $(0.26),per share on a ...
... Resources on Partnership to Develop Rapid Molecular ... Tests for Healthcare-Associated Infections -, SAN DIEGO, Nov. 8 ... informed the Company it no longer intends to,fund the companies, ... The companies expect to formally terminate the,collaboration in the coming ...
... Approve Sale of Nabi ... Biologics to Biotest, ... today announced its third quarter,financial results. The company recorded a net ... September 29, 2007, which included,$7.5 million, or $0.12 per share, of ...
... Hispanic youth report better dental health habits than their non-Hispanic ... researchers at Columbia University Mailman School of Public Health. ... the Journal of Health Care for the Poor and Underserved, ... community in America. , The study, a snapshot of more ...
Cached Medicine News:Health News:Response Genetics to Announce Third Quarter 2007 Financial Results on Wednesday, November 14, 2007 2Health News:California Restaurant Association Chooses EMPLOYERS(R) as its New Provider of Choice for Members' Workers' Compensation Insurance Needs 2Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 2Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 3Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 4Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 5Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 6Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 7Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 8Health News:3M, Gen-Probe to Discontinue Molecular Food Testing Collaboration 2Health News:3M, Gen-Probe to Discontinue Molecular Food Testing Collaboration 3Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 2Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 3Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 4Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 5Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 6Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 7Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 8Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 9Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 10Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 11Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 12Health News:Study of minority New York City youth finds unequal burden of poor dental health 2
... and fabric specialty drapes for ... Steri-Drape absorbent prevention fabric creates ... strike-through reducing the need for ... Pack, Op tape, Hand towels, ...
... The table top design takes into ... and creates a flexible working environment for ... the alphamaxx can be matched exactly to ... top slide capability creates superior access for ...
... DePuy Mitek is the Market leader ... With ORTHOCORD Suture, DePuy Mitek has developed ... arthroscopic and open shoulder repair. ORTHOCORD Suture ... suture on the market. Most importantly, ORTHOCORD ...
... Now you can ... tactile sensitivity of the ... Free surgical gloves on ... Free gloves provide the ...
Medicine Products: